Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CarMax, Inc (KMX) vs Eli Lilly And Co (LLY) Price & Performance

CarMax, IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

CarMax, Inc vs Eli Lilly And Co — how do they compare? CarMax, Inc trades at $58.48 (market cap $8.26B), while Eli Lilly And Co trades at $1,222.27 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 130.8× CarMax, Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.

KMXLLY
Market Cap
$8.26B$1.08T
Sector
Consumer CyclicalHealth
52-Week High
$62.17$1.24K
52-Week Low
$30.88$639.43
Enterprise Value
$26.77B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CarMax, Inc

CarMax (KMX) trades at $58.20, showing modest near-term weakness with a 0.99% daily decline. The stock maintains a bullish technical stance with strong moving average support and trades near key support at $58. Fundamentally, the company reported Q1 2026 earnings beat with $0.34 EPS versus $0.23 expected, though revenue trends show slight contraction from $26.4B in 2025 to projected $26.3B in 2026. Recent positive developments include AI partnership enhancements and strong institutional recognition.

CarMax presents a mixed investment case with technical strength offset by fundamental challenges. The bullish moving average configuration and recent earnings beats provide near-term support, but declining revenue trends and thin 0.84% net margin limit upside potential. Key risks include ongoing fiduciary investigations and competitive pressure in the used car market. Analyst consensus remains cautious with 68.6% hold ratings and $53.09 price target below current levels.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CarMax, Inc

CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.

Read more on KMX

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY